Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 11/20 | 0.35 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472074 | 0.88 | SMN1; SMN2 (0.38) | DAGLAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4163254 | 0.88 | DPP4 (0.39) | DPP4DAGLADAGLBABHD6MEN1 | |
| SCHEMBL2124842 | 0.86 | PDE8B (0.40) | DAGLAMEN1KMT2A | |
| SCHEMBL4157352 | 0.82 | MEN1 (0.40) | DPP4DAGLAABHD6MEN1NPC1 | |
| SCHEMBL3470606 | 0.77 | ALDH1A1 (0.39) | DAGLAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4165845 | 0.77 | KDM4E (0.41) | DPP4DAGLADAGLBABHD6MEN1 | |
| SCHEMBL4167405 | 0.75 | ALDH1A1 (0.38) | DAGLAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL2517432 | 0.75 | PDE8B (0.41) | MEN1KMT2A | |
| SCHEMBL2120886 | 0.75 | PDE8B (0.41) | MEN1KMT2A | |
| SCHEMBL2616581 | 0.71 | HCRTR1 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022670-A1 | NOVEL COMPOUNDS | UGT1A1, UGT2B7, ABCB1 | DPP4 612/4885DAGLA 4103/4885DAGLB 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.